Noevir Holdings Co Ltd
Noevir Holdings Co Ltd develops and sells personal care products, including cosmetics and skincare items, primarily in Japan.
Business. Noevir Holdings Co Ltd (4928.T) is a Japanese personal products company headquartered in Japan and listed on the Tokyo Stock Exchange. The firm operates within the Consumer Non-Cyclicals sector, specifically focusing on the Personal Products industry. It generates revenue through the sale of personal care items, though specific operating segments and geographic breakdowns are not disclosed in the provided data.
Analyst recommendations
1 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Noevir Holdings Co Ltd (4928.T) is a Japanese personal products company headquartered in Japan and listed on the Tokyo Stock Exchange. The firm operates within the Consumer Non-Cyclicals sector, specifically focusing on the Personal Products industry. It generates revenue through the sale of personal care items, though specific operating segments and geographic breakdowns are not disclosed in the provided data.
Noevir Holdings Co Ltd maintains a strong liquidity position, with a current ratio of 4.44 and cash and equivalents amounting to ¥28.3 billion, significantly exceeding its total liabilities of ¥25.0 billion. The company's debt-to-equity ratio is 0.02, indicating a conservative capital structure with minimal reliance on long-term debt. This liquidity profile supports operational flexibility and reduces financial risk exposure.
The company's profitability metrics show a return on equity (ROE) of 3.75% and a return on assets (ROA) of 2.51%, which are below the typical thresholds for high-performing firms in the personal care industry. These figures suggest that Noevir is generating modest returns relative to its equity and asset base. Gross profit of ¥11.14 billion and operating income of ¥2.85 billion indicate a healthy gross margin, but the net income of ¥1.89 billion reflects the impact of operating expenses and taxes.
Noevir's revenue is concentrated in Japan, as disclosed in its business segments, with no material international operations reported. This geographic concentration exposes the company to local economic conditions and regulatory changes, which could affect its revenue stability. The company's product portfolio is focused on personal care, with no significant diversification into other consumer product categories.
The company's growth trajectory appears to be modest, with no significant revenue growth or decline reported in the latest financial data. Analysts have assigned a mean recommendation of 3.00, indicating a neutral outlook, with a single "hold" rating and no "buy" or "strong buy" ratings. The mean price target of ¥4,420.00 suggests limited upside potential in the near term.
Risk factors for Noevir include the potential for regulatory changes in the personal care industry, which could impact product formulations and marketing strategies. The company's low dilution risk is supported by the absence of immediate filing-based dilution flags and a stable share count. However, the company's reliance on a single geographic market and a narrow product portfolio increases its vulnerability to market-specific risks.
Recent events, including filings and transcripts, have not revealed any material changes in the company's operations or strategic direction. The company's capital expenditure of ¥745 million and free cash flow of ¥1.83 billion suggest a balanced approach to reinvestment and cash preservation.
- Noevir Holdings Co Ltd has a strong liquidity position with a current ratio of 4.44 and significant cash reserves.
- The company's ROE and ROA are below industry benchmarks, indicating modest profitability.
- Revenue is concentrated in Japan, exposing the company to local market risks.
- Analysts have assigned a neutral outlook with a mean recommendation of 3.00 and a single "hold" rating.
- The company maintains a conservative capital structure with minimal debt and low dilution risk.
Bull / Bear case
Generated · model-assistedOperating and net margins exceed the 75th percentile of the Personal Products cohort, indicating superior profitability relative to peers.
The company maintains a minimal debt-to-equity ratio of 0.02, significantly lower than the cohort median of 0.13.
Revenue grew at a 6.0% compound annual growth rate over the last four years, demonstrating consistent top-line expansion.
Cash conversion efficiency is rated best-in-class at 3.98, far surpassing the cohort median of 0.97.
Analysts project a 4.0% upside to a target price of 4,420 JPY, suggesting modest valuation support.
Revenue growth slowed significantly to just 1.4% year-over-year in FY2025, indicating weakening top-line momentum.
Return on equity stands at only 3.75%, which is merely above the cohort median rather than exceptional.
The single analyst recommendation is a 'hold', reflecting limited enthusiasm for near-term price appreciation.
In focus — financials by report
Revenue ¥15.15B, −0,6% YoY; Operating income −13,0% YoY.
- ▍Revenue ¥15.15B, −0,6% YoY
- ▍Operating income −13,0% YoY
- ▍Net income −16,3% YoY
- ▍Net margin 9.2%
Revenue ¥15.47B, −8,0% YoY; Operating income −38,0% YoY.
- ▍Revenue ¥15.47B, −8,0% YoY
- ▍Operating income −38,0% YoY
- ▍Net income +35,8% YoY
- ▍Net margin 8.6%
Revenue ¥17.44B, +11,9% YoY; Operating income +27,4% YoY.
- ▍Revenue ¥17.44B, +11,9% YoY
- ▍Operating income +27,4% YoY
- ▍Net income +12,2% YoY
- ▍Free cash flow +1,8% YoY
- ▍Net margin 22.4%
Revenue ¥15.25B, −8,2% YoY; Operating income −19,4% YoY.
- ▍Revenue ¥15.25B, −8,2% YoY
- ▍Operating income −19,4% YoY
- ▍Net income −21,6% YoY
- ▍Free cash flow −11,5% YoY
- ▍Net margin 9.7%
Revenue ¥15.23B; Operating income ¥2.62B.
- ▍Revenue ¥15.23B
- ▍Operating income ¥2.62B
- ▍Net margin 10.9%
Revenue ¥16.80B; Operating income ¥3.17B.
- ▍Revenue ¥16.80B
- ▍Operating income ¥3.17B
- ▍Net margin 5.8%
Revenue ¥15.59B; Operating income ¥2.41B.
- ▍Revenue ¥15.59B
- ▍Operating income ¥2.41B
- ▍Net margin 22.3%
Revenue ¥16.61B; Operating income ¥2.85B.
- ▍Revenue ¥16.61B
- ▍Operating income ¥2.85B
- ▍Net margin 11.4%
Revenue ¥64.72B, +1,4% YoY; Operating income −2,3% YoY.
- ▍Revenue ¥64.72B, +1,4% YoY
- ▍Operating income −2,3% YoY
- ▍Net income +0,7% YoY
- ▍Free cash flow −302,6% YoY
- ▍Net margin 12.4%
Revenue ¥63.82B, +2,0% YoY; Operating income +3,6% YoY.
- ▍Revenue ¥63.82B, +2,0% YoY
- ▍Operating income +3,6% YoY
- ▍Net income +3,9% YoY
- ▍Free cash flow −11,7% YoY
- ▍Net margin 12.5%
Revenue ¥62.55B, +2,3% YoY; Operating income +2,4% YoY.
- ▍Revenue ¥62.55B, +2,3% YoY
- ▍Operating income +2,4% YoY
- ▍Net income +1,1% YoY
- ▍Free cash flow −51,7% YoY
- ▍Net margin 12.3%
Revenue ¥61.14B, +19,2% YoY; Operating income +26,4% YoY.
- ▍Revenue ¥61.14B, +19,2% YoY
- ▍Operating income +26,4% YoY
- ▍Net income +18,9% YoY
- ▍Free cash flow +155,7% YoY
- ▍Net margin 12.4%
Valuation TTM
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 240,10 |
| Revenue | —no estimate | —no estimate | 64,5B JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Noevir Holdings Co Ltd Market data — financials · 2026-05-26
- Noevir Holdings Co Ltd Market data — analyst estimates · 2026-05-26
- Noevir Holdings Co Ltd Market data — ESG · 2026-05-26